HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

KVUE

Kenvue Inc. (NYSE)

Consumer Defensive — Household & Personal Products

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Hold 2.8 / 5 12 analysts
$19.33
+$0.22 (+1.15%)
Target: $19.50 (0.9%)
Sign in to add KVUE to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$37.11B
P/E Ratio (TTM)23.01
Forward P/E15.63
EPS (TTM)$0.84
Dividend Yield4.29%
Profit Margin10.61%
Revenue Growth4.50%
ROE15.70%
Debt/Equity82.98
Recommendation Hold 2.8
Analyst Target$19.50
Analysts12
Indexes NYSE

Technical Indicators

RSI (14)73.2
Beta0.50
SMA 20-
SMA 40-
52-Week High$22.87
52-Week Low$14.02
50-Day Avg$17.73
200-Day Avg$17.26
Avg Volume$20.22M
Volume$14.37M

Performance Analysis

NEUTRAL

KVUE presents a mixed picture with both positive and negative indicators.

~ Trading at 60% of its 52-week range.
- RSI at 73.2 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 4.5% year-over-year.
~ Wall Street consensus is "Hold" from 12 analysts.
+ Average analyst target of $19.50 implies 0.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:17 UTC

Back to Screener Export Report